Amarin Corporation plc announced the appointment of Adam Berger and Geraldine Murphy as independent members of the Company's Board of Directors, effective immediately. The Company also announced that, as part of their planned retirement, Lars Ekman, M.D., Ph.D and Patrick O'Sullivan, directors of Amarin since 2008 and 2011, respectively, will retire from the Board, effective at the end of the year. With these changes, the Amarin Board will remain at eight directors, seven of whom are independent and five of whom have been appointed in the past year as part of the Board replenishment process which seeks to add international experience to support the company's global expansion efforts.

Mr. Berger has more than three decades of experience with investment banking focused on mergers and acquisitions. He has advised on over 180 announced M&A transactions predominantly in the healthcare industry totaling more than $400 billion in value and has significant experience with capital markets transactions and generating value for company shareholders. Mr. Berger also brings a unique perspective and skill set as a former Chairman of Wells Fargo's Investment Banking Opinion Committee.

Ms. Murphy brings more than 30 years of experience as a healthcare company executive across core business areas including manufacturing, supply chain, P&L management, and commercial strategy. Ms. Murphy has a strong focus on people and organizational development which will be of significant value to Amarin and the Amarin Board.